BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuntzen T, Kuhn S, Kuntzen D, Seifert B, Müllhaupt B, Geier A. Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. PLoS One 2016;11:e0158512. [PMID: 27388623 DOI: 10.1371/journal.pone.0158512] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Guardigni V, Badia L, Conti M, Rinaldi M, Mancini R, Viale P, Verucchi G. Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals. World J Hepatol 2017; 9(34): 1270-1277 [PMID: 29290908 DOI: 10.4254/wjh.v9.i34.1270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 van Tilborg M, Lieveld FI, Smolders EJ, van Erpecum KJ, de Kanter CTMM, Maan R, van der Valk M, Arends JE, Dofferhoff ASM, Blokzijl H, Bijmolen M, Drenth JPH, de Knegt RJ, Burger DM; HepNed Study Group. Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. Aliment Pharmacol Ther 2017;46:864-72. [PMID: 28881031 DOI: 10.1111/apt.14288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Ibrahim Mohammed Ebid AH, Ashraf Ahmed O, Hassan Agwa S, Mohamed Abdel-Motaleb S, Mohamed Elsawy A, Hagag RS. Safety, efficacy and cost of two direct-acting antiviral regimens: A comparative study in chronic hepatitis C Egyptian patients. J Clin Pharm Ther 2020;45:539-46. [PMID: 31889322 DOI: 10.1111/jcpt.13104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Lobato CMO, Balassiano N, Hyppolito EB, Sanchez-Lermen RLP, Signorelli IV, Nicacio MYT, Firmino Filho AP, Andrade TG, Lima JMC, Arruda TA, Coutinho FS, Araujo EFDV, Esmeraldo TM, Cortez E, Capeli RLA, Matos MBM, Pessoa FSR, Oliveira HC, Arruda ÉAG, Gonçalves PL, Araújo Filho AH, Esberard EBC, Souto FJD. Effectiveness of first-wave protease inhibitors in hepatitis C virus genotype 1 infection: a multicenter study in Brazil. Rev Soc Bras Med Trop 2018;51:14-20. [PMID: 29513836 DOI: 10.1590/0037-8682-0279-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Tanaka Y, Inoue A, Mizunuma T, Matsumura H, Yokomori H, Komiyama T, Otori K. Tolerability of Erythrocyte Ribavirin Triphosphate Concentrations Depends on the ITPA Genotype. Ther Drug Monit 2019;41:497-502. [PMID: 30817703 DOI: 10.1097/FTD.0000000000000626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
7 Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs. Hepatol Res 2019;49:1275-85. [PMID: 31261439 DOI: 10.1111/hepr.13401] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]